2017 Annual Meeting

Molecular Diagnostic and Genomic Applications in Cancer: A Primer for the Pathologist

Room Hemisfair 2, March 7 2017, 8:00am to 5:15pm

Description

Molecular Diagnostic and Genomic Applications in Cancer: A Primer for the Pathologist
Tuesday, March 7, 2017
8:00 AM 5:15 PM
CC Hemisfair 2

 

Session Credits: CME and SAMs

 

Course Directors: George J. Netto, MD, The University of Alabama at Birmingham, Birmingham, AL
Karen Kaul, MD, PhD, North Shore University Health System, Evanston, IL

Course Description:
The pathologist is increasingly expected to play a central role in the management of cancer patients in the era of personalized oncology. Molecular diagnostic and genomic applications are rapidly penetrating the daily practice of the pathologist as the list of actionable genetic alteration in solid and hematologic tumors continues to expand. As highlighted in the USCAP 2012 combined companion meeting of “the Association for Molecular Pathology Joint Meeting with American Society for Clinical Pathology in Coordination with American Society for Investigative Pathology”, efforts to develop residency curricula that will address the educational needs in molecular and genomic pathology for pathologists in training are underway by some academic institutions and others. These initiatives include the efforts sponsored by the Training Residents in Genomics (TRIG) working group of the Pathology Residency Directors Section of the Association of Pathology Chairs. Similar educational needs are evident among practicing pathologists in the community and academic centers, pathology residents and fellows in institutions that are yet to develop a formal curriculum. A survey of the positive responses from attendees of the “sold out” special course titled “Basic Principles and Practice of Molecular Pathology in Cancer”, which was in its final iteration at USCAP 2012, is very indicative of an urgent and important educational need. The current course proposal intends to build upon and extend the role that the latter course, that is no longer offered, fulfilled. In fact, the proposal stems from the shared recognition of the AMP, ASIP and ASCP organizations that sponsored the 2012 combined companion meeting and from the director and faculty of the previous special course that there is the continuous need to offer educational opportunities to augment medical knowledge and to address competency deficiencies among the intended target audience, which is, primarily, the group of anatomic pathologists.

Upon completion of this educational activity, participants should be able to:

  • Select the appropriate and most cost-effective molecular and cytogenetic testing for workup of lymphomas and tissue-based leukemic infiltrates of various types
  • Assess the technology, limitations and benefits of next generation mutation, array and transcriptional profiling in lymphomas
  • Describe the emerging role of exome/whole genome sequencing in the management of patients with lymphoma

 

Agenda

8:00 AM

Introduction
George J. Netto, MD, The University of Alabama at Birmingham, Birminham, AL

8:10 AM

Current Next Generation Sequencing Technology: A Primer to the Anatomic Pathologist
Wayne W. Grody, MD, PhD, University of California Los Angeles School of Medicine, Los Angeles, CA
Upon completion of this educational activity, participants should be able to:

  • Discuss the overall principles of massively parallel sequencing (next generation sequencing) technologies
  • Illustrate practical examples of NGS based clinical diagnostics and how it will be impacting daily practice of pathology

8:50 AM

Next-Gen Surgical Pathology: New Opportunities and Challenges
Karen Kaul, MD, PhD, North Shore University Health System, Evanston, IL
Upon completion of this educational activity, participants should be able to:

  • Discuss how the evolving understanding of molecular events underlying cancer development is making molecular characterization of tumors a necessity for diagnosis and prognostication in the practice of the pathologist
  • Present an overview of the evolution of molecular testing from single gene or mutation analysis to multiplex capabilities including next generation sequencing
  • Discuss the challenges and opportunities associated with the incorporation of these tools into the daily practice of the pathologist

9:20 AM

Molecular Markers for Targeted Lung Cancer Therapy
John Iafrate, MD, PhD, Massachusetts General Hospital, Boston, MA
Upon completion of this educational activity, participants should be able to:

  • State the current genetic landscape of lung tumors
  • Identify the role of genetic testing in guiding targeted therapies in lung cancer
  • Appreciate the importance of advanced technologies in the future of pathologic assessment of tumors

10:00 AM

Break/Poster Session

10:30 AM

Molecular Testing in the Management of Patients with Breast Cancer: Current Status and Future Directions
Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA
Upon completion of the educational activity, participants should be able to:

  • Explain the molecular classification of breast cancer and its clinical implications
  • Review the uses and limitations of currently available molecular prognostic tests for patients with breast cancer
  • Describe the emerging role of exome /whole genome sequencing in the management of patients with breast cancer

11:00 AM

Clinical Cytogenetic and Molecular Genetic Testing in Bone and Soft Tissue Tumors
Julia A. Bridge, MD, University of Nebraska Medical Center, Omaha, NE
Upon completion of this educational activity, participants should be able to:

  • Review sample requirements and handling for RT-PCF, FISH, and cytogenetic analysis as they pertain to evaluating mesenchymal neoplasms
  • Describe the advantages and limitations of genetic approaches commonly used in the classification of mesenchymal neoplasms to include conventional karyotyping, FISH and RT-PCR
  • Recognize the diagnostic, prognostic, and therapeutic value of molecular markers in mesenchymal neoplasia

11:40 AM

GIST and Melanoma: The KIT Connection and So Much More
Alexander Lazar, MD, PhD, University of Texas, M. D. Anderson Cancer Center, Houston, TX

Upon completion of this educational activity, participants should be able to:

  • Illustrate the techniques and results of molecular testing for gastrointestinal stromal tumor (GIST) and melanoma
  • Recognize the association between histologic and molecular features in GIST and melanoma
  • Interpret the emerging role of molecular diagnostics in patient management for GIST and melanoma

12:10 PM

Lunch Break

1:10 PM

Molecular Diagnostics of Lymphoma: Assays for Classification, Outcome Prediction and Therapy Response
Dan Jones, MD, PhD, The Ohio State University College of Medicine, Columbus, OH

Upon completion of this educational activity, participants should be able to:

  • Select the appropriate and most cost-effective molecular and cytogenetic testing for workup of lymphomas and tissue-based leukemic infiltrates of various types
  • Assess the technology, limitations and benefits of next generation mutation, array and transcriptional profiling in lymphomas
  • Describe the emerging role of exome/whole genome sequencing in the management of patients with lymphoma

1:50 PM

Colorectal Cancer: Molecular Testing for the Surgical Pathologist
Kevin C. Halling, MD, PhD, Mayo Clinic, Rochester, MN
Upon completion of this educational activity, participants should be able to:

  • Discuss how MSI and DNA mismatch repair IHC testing and germline DNA mismatch repair gene sequencing are used to identify, diagnose, and manage patients with HNPCC
  • Explain how microsatellite instability testing can be used to assess stage II and III CRC patients’ prognosis and response to 5FU treatment.
  • Describe how KRAS and BRAF testing can be used to predict response to anti-EGFR therapies for patients with metastatic colorectal cancer (CRC)
  • Describe the emerging role of exome/whole genome sequencing in the management of patients with colorectal cancer

2:30 PM

Emerging Immunologic Biomarkers: PD-L1 and Beyond
Janis Taube, MD PhD, The Johns Hopkins University, Baltimore, MD
Upon completion of this educational activity, participants should be able to:

  • Introduce the CTLA-4/CD80 or CD86 and PD-1/PD-L1 checkpoints, including physiologic and pathologic expression
  • Discuss the association of immunoarchitectural features of the tumor microenvironment and relationship to response with anti-PD-1/PD-L1 checkpoint blockade
  • Compare available assays for PD-L1 detection in surgical pathology specimens

3:00 PM

Break/Poster Session

3:30 PM

Molecular Diagnostics of CNS Tumors
Arie Perry, MD, University of California San Francisco School of Medicine, San Francisco, CA
Upon completion of this educational activity, participants should be able to:

  • Review the most common molecular alterations in CNS tumors
  • Recognize the association between histologic and molecular features in CNS tumors
  • Interpret the emerging role of molecular diagnostics in patient management for CNS tumors

4:00 PM

Role of the Pathologist in Guiding Immuno-Oncological Therapies
Scott Rodig, MD, PhD, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Upon completion of this educational activity, participants should be able to:

  • Review clinical outcomes in melanoma, lung cancer, bladder cancer, hematological malignancies to novel immunotherapies.
  • Discuss histopathological and genetic correlates leukemia of clinical response to immunotherapy.
  • Review current applications of diagnostic pathological methods to guide immunotherapy.
  • Describe development of future diagnostic methods to guide immunotherapy.

4:30 PM

Molecular Diagnostics of Head and Neck Tumors
Justin Bishop, MD, Johns Hopkins University, Baltimore, MD
Upon completion of this educational activity, participants should be able to:

  • Review HPV-related Oropharyngeal SCC entities (locations, prognosis, histology)
  • Discuss HPV testing strategies in the Head & Neck tumors.
  • Discuss newly described tumor-defining translocations in salivary gland tumors.

5:00 PM

Question Period and Concluding Remarks
George J. Netto, MD, The University of Alabama at Birmingham, Birmingham, AL

Meetings

home-circle-inset-1
view more